CRO Crown Bioscience Adds Kannapolis Site

Crown Bioscience, a global contract research organization (CRO), is expanding its U.S. footprint with a new site in Kannapolis, North Carolina. The facility will focus on preclinical oncology services, including in vivo pharmacology and biomarker analysis to support the growing demand for translational research. This move not only strengthens Crown Bioscience’s capabilities in cancer drug development but also taps into the region’s life sciences talent and infrastructure. The Kannapolis site is expected to enhance collaboration with academic and industry partners, accelerating innovation in oncology therapeutics. For teams tracking CRO trends or evaluating partners in preclinical oncology, discover how this expansion signals a strategic investment in scientific depth and geographic reach.